SK said we have data that is attracting a lot of attention from big pharma. But don't expect any cancer trial deals with big pharma until after the approval to increase available shares. CYDY and big pharma are unable to come to an agreement about what fair value each brings to the table. Fine by me. After AS raise approval and after more results, big pharma will need to value CYDY even 'more' fairly. Of course, this has to weigh on the minds of big pharma who want to avoid a bidding war to partner with CYDY.

Anyone vociferously against how NP/have SK raised/raising funds is just gas lighting you. Everyone who has ever invested in penny stocks and in particular biotech companies is familiar with death spiral financing, which is what previous management believed in....probably because they were lazy lemmings just going with the status quo.

The cancer testimonial at ~8:05 blows my mind.

Revenue from the Philippines is ramping and I bet its doing so exponentially.

What will be first?
- EUA from the Philippines?
- Great results from the Brazil trials?
- Great results from the NASH study?
- Great results from long haulers study?
- Update about $1m in total revenues from the Phillipines?
- something else I can't keep track of?